Protocols

Reeling Ophthotech eviscerates staff, laying off up to 135; Booming Regeneron adds more space

Four days after Ophthotech stock $OPHT cratered in the wake of a Phase III debacle for its wet, age-related macular degeneration drug Fovista, the biotech’s back with a restructuring plan that includes laying off up to 135 staffers and terminating much of the clinical trial work now underway. The second 12-month stage of the Fovista Phase III has been terminated, along with its clinical work combining Fovista with anti-VEGF drugs in its expansion trials. It will continue a late-stage study combining Fovista with Eylea or Avastin. When the restructuring is over, the New York-based biotech will have a staff of only 20 to 30 employees.

A booming Regeneron $REGN has snapped up an office building and 76-acre site in Westchester for its fast-growing operations. The biotech, closely allied with Sanofi, has been adding staff as it grows its portfolio of approved drugs.

Cancer Research UK’s Centre for Drug Development is funding a Phase Ia and Phase Ib clinical trial for a drug called BT1718, a drug conjugate being developed by Bicycle Therapeutics, in patients with advanced solid tumours. BT1718 targets Membrane Type 1 Matrix Metalloproteinase, which is expressed in many solid tumors, including triple negative breast cancer and non-small cell lung cancer.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->